Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania
Tyrosine kinase inhibitor (TKI) discontinuation in chronic phase chronic myeloid leukemia (CML) patients has been examined in a real-life setting in the east occitania region of France. We have collected sex, age, prognostic scores, pre-TKI treatment, TKI length and response, relapse data from patie...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2022-05, Vol.101 (5), p.1015-1022 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1022 |
|---|---|
| container_issue | 5 |
| container_start_page | 1015 |
| container_title | Annals of hematology |
| container_volume | 101 |
| creator | Robin, J. B. Theron, A. Quittet, P. Exbrayat, C. Gaillard, J. B. Lavabre-Bertrand, T. David, S. Saad, A. Jourdan, E. Cartron, G. |
| description | Tyrosine kinase inhibitor (TKI) discontinuation in chronic phase chronic myeloid leukemia (CML) patients has been examined in a real-life setting in the east occitania region of France. We have collected sex, age, prognostic scores, pre-TKI treatment, TKI length and response, relapse data from patients who had stopped TKI in prolonged complete molecular remission (CMR), and analyzed relapse risk factors. Sixty consecutive patients were included from january 2010 to december 2016. Sixteen received pre-TKI treatment. Fifty-three received a first-generation TKI, and seven had a second-generation TKI in first-line therapy. The median TKI time to achieve CMR was 20.5 months [5–137]. The median TKI length before discontinuation treatment was 73 months [12–158]. Twenty-two patients (37%) relapsed with a median time to relapse of 6 months [3–27]. An intermediate or high Sokal score was the only relapse risk factor (HR = 3.32,
p
|
| doi_str_mv | 10.1007/s00277-022-04779-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04086518v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2648322798</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-12773a414bfedd8011452dec0eab86782aa73128cb71e78ce81e4ce962bfcad93</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhS0EokPhD7BAltiURYpfGdvsqkJppZHYwNpynBvGbWIPtlN1_n09pC0Si3rj13eOfe9B6D0lp5QQ-TkTwqRsCGMNEVLq5u4FWlHB67ZV4iVaEc1109ZxhN7kfE0IZUqw1-iIt0wqovUKpa8-uxiKD7MtPgYcB1z2KWYfAN_4YDNgH7a-8yWmusJum2LwDk97GKPv8QjzDUzefsEWJyhVuQNX_C1gF7cxlYMGbC44OueLDd6-Ra8GO2Z49zAfo18X336eXzabH9-vzs82jRNEl4bW2rgVVHQD9L0ilIqW9eAI2E6tpWLWSl4Lcp2kIJUDRUE40GvWDc72mh-jT4vv1o5ml_xk095E683l2cYczoggat1SdUsre7KwuxT_zJCLmWpfYBxtgDhnw9ZcSaEYJRX9-B96HecUaiWVEoozJrWqFFsoVzuSEwxPP6DEHNIzS3qmpmf-pmfuqujDg_XcTdA_SR7jqgBfgFyvwm9I_95-xvYeQ0Wm6A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2648322798</pqid></control><display><type>article</type><title>Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Robin, J. B. ; Theron, A. ; Quittet, P. ; Exbrayat, C. ; Gaillard, J. B. ; Lavabre-Bertrand, T. ; David, S. ; Saad, A. ; Jourdan, E. ; Cartron, G.</creator><creatorcontrib>Robin, J. B. ; Theron, A. ; Quittet, P. ; Exbrayat, C. ; Gaillard, J. B. ; Lavabre-Bertrand, T. ; David, S. ; Saad, A. ; Jourdan, E. ; Cartron, G.</creatorcontrib><description>Tyrosine kinase inhibitor (TKI) discontinuation in chronic phase chronic myeloid leukemia (CML) patients has been examined in a real-life setting in the east occitania region of France. We have collected sex, age, prognostic scores, pre-TKI treatment, TKI length and response, relapse data from patients who had stopped TKI in prolonged complete molecular remission (CMR), and analyzed relapse risk factors. Sixty consecutive patients were included from january 2010 to december 2016. Sixteen received pre-TKI treatment. Fifty-three received a first-generation TKI, and seven had a second-generation TKI in first-line therapy. The median TKI time to achieve CMR was 20.5 months [5–137]. The median TKI length before discontinuation treatment was 73 months [12–158]. Twenty-two patients (37%) relapsed with a median time to relapse of 6 months [3–27]. An intermediate or high Sokal score was the only relapse risk factor (HR = 3.32,
p
< 0.05) associated with relapse after TKI discontinuation. TKI discontinuation was possible without relapse for half of the patients in chronic phase CML. In a real-life cohort, a high-risk Sokal score at diagnosis appears to be an adverse prognosis feature for TKI discontinuation.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-022-04779-x</identifier><identifier>PMID: 35278099</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Hematology ; Humans ; Kinases ; Laboratories ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - chemically induced ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology ; Leukemia, Myeloid, Chronic-Phase ; Life Sciences ; Medical prognosis ; Medicine ; Medicine & Public Health ; Oncology ; Original Article ; Protein Kinase Inhibitors - adverse effects ; Recurrence ; Remission (Medicine) ; Retrospective Studies ; Stem cells</subject><ispartof>Annals of hematology, 2022-05, Vol.101 (5), p.1015-1022</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-12773a414bfedd8011452dec0eab86782aa73128cb71e78ce81e4ce962bfcad93</citedby><cites>FETCH-LOGICAL-c409t-12773a414bfedd8011452dec0eab86782aa73128cb71e78ce81e4ce962bfcad93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-022-04779-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-022-04779-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35278099$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04086518$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Robin, J. B.</creatorcontrib><creatorcontrib>Theron, A.</creatorcontrib><creatorcontrib>Quittet, P.</creatorcontrib><creatorcontrib>Exbrayat, C.</creatorcontrib><creatorcontrib>Gaillard, J. B.</creatorcontrib><creatorcontrib>Lavabre-Bertrand, T.</creatorcontrib><creatorcontrib>David, S.</creatorcontrib><creatorcontrib>Saad, A.</creatorcontrib><creatorcontrib>Jourdan, E.</creatorcontrib><creatorcontrib>Cartron, G.</creatorcontrib><title>Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>Tyrosine kinase inhibitor (TKI) discontinuation in chronic phase chronic myeloid leukemia (CML) patients has been examined in a real-life setting in the east occitania region of France. We have collected sex, age, prognostic scores, pre-TKI treatment, TKI length and response, relapse data from patients who had stopped TKI in prolonged complete molecular remission (CMR), and analyzed relapse risk factors. Sixty consecutive patients were included from january 2010 to december 2016. Sixteen received pre-TKI treatment. Fifty-three received a first-generation TKI, and seven had a second-generation TKI in first-line therapy. The median TKI time to achieve CMR was 20.5 months [5–137]. The median TKI length before discontinuation treatment was 73 months [12–158]. Twenty-two patients (37%) relapsed with a median time to relapse of 6 months [3–27]. An intermediate or high Sokal score was the only relapse risk factor (HR = 3.32,
p
< 0.05) associated with relapse after TKI discontinuation. TKI discontinuation was possible without relapse for half of the patients in chronic phase CML. In a real-life cohort, a high-risk Sokal score at diagnosis appears to be an adverse prognosis feature for TKI discontinuation.</description><subject>Hematology</subject><subject>Humans</subject><subject>Kinases</subject><subject>Laboratories</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - chemically induced</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology</subject><subject>Leukemia, Myeloid, Chronic-Phase</subject><subject>Life Sciences</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Recurrence</subject><subject>Remission (Medicine)</subject><subject>Retrospective Studies</subject><subject>Stem cells</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kUtv1DAUhS0EokPhD7BAltiURYpfGdvsqkJppZHYwNpynBvGbWIPtlN1_n09pC0Si3rj13eOfe9B6D0lp5QQ-TkTwqRsCGMNEVLq5u4FWlHB67ZV4iVaEc1109ZxhN7kfE0IZUqw1-iIt0wqovUKpa8-uxiKD7MtPgYcB1z2KWYfAN_4YDNgH7a-8yWmusJum2LwDk97GKPv8QjzDUzefsEWJyhVuQNX_C1gF7cxlYMGbC44OueLDd6-Ra8GO2Z49zAfo18X336eXzabH9-vzs82jRNEl4bW2rgVVHQD9L0ilIqW9eAI2E6tpWLWSl4Lcp2kIJUDRUE40GvWDc72mh-jT4vv1o5ml_xk095E683l2cYczoggat1SdUsre7KwuxT_zJCLmWpfYBxtgDhnw9ZcSaEYJRX9-B96HecUaiWVEoozJrWqFFsoVzuSEwxPP6DEHNIzS3qmpmf-pmfuqujDg_XcTdA_SR7jqgBfgFyvwm9I_95-xvYeQ0Wm6A</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Robin, J. B.</creator><creator>Theron, A.</creator><creator>Quittet, P.</creator><creator>Exbrayat, C.</creator><creator>Gaillard, J. B.</creator><creator>Lavabre-Bertrand, T.</creator><creator>David, S.</creator><creator>Saad, A.</creator><creator>Jourdan, E.</creator><creator>Cartron, G.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>20220501</creationdate><title>Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania</title><author>Robin, J. B. ; Theron, A. ; Quittet, P. ; Exbrayat, C. ; Gaillard, J. B. ; Lavabre-Bertrand, T. ; David, S. ; Saad, A. ; Jourdan, E. ; Cartron, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-12773a414bfedd8011452dec0eab86782aa73128cb71e78ce81e4ce962bfcad93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Hematology</topic><topic>Humans</topic><topic>Kinases</topic><topic>Laboratories</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - chemically induced</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology</topic><topic>Leukemia, Myeloid, Chronic-Phase</topic><topic>Life Sciences</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Recurrence</topic><topic>Remission (Medicine)</topic><topic>Retrospective Studies</topic><topic>Stem cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Robin, J. B.</creatorcontrib><creatorcontrib>Theron, A.</creatorcontrib><creatorcontrib>Quittet, P.</creatorcontrib><creatorcontrib>Exbrayat, C.</creatorcontrib><creatorcontrib>Gaillard, J. B.</creatorcontrib><creatorcontrib>Lavabre-Bertrand, T.</creatorcontrib><creatorcontrib>David, S.</creatorcontrib><creatorcontrib>Saad, A.</creatorcontrib><creatorcontrib>Jourdan, E.</creatorcontrib><creatorcontrib>Cartron, G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Robin, J. B.</au><au>Theron, A.</au><au>Quittet, P.</au><au>Exbrayat, C.</au><au>Gaillard, J. B.</au><au>Lavabre-Bertrand, T.</au><au>David, S.</au><au>Saad, A.</au><au>Jourdan, E.</au><au>Cartron, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>101</volume><issue>5</issue><spage>1015</spage><epage>1022</epage><pages>1015-1022</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Tyrosine kinase inhibitor (TKI) discontinuation in chronic phase chronic myeloid leukemia (CML) patients has been examined in a real-life setting in the east occitania region of France. We have collected sex, age, prognostic scores, pre-TKI treatment, TKI length and response, relapse data from patients who had stopped TKI in prolonged complete molecular remission (CMR), and analyzed relapse risk factors. Sixty consecutive patients were included from january 2010 to december 2016. Sixteen received pre-TKI treatment. Fifty-three received a first-generation TKI, and seven had a second-generation TKI in first-line therapy. The median TKI time to achieve CMR was 20.5 months [5–137]. The median TKI length before discontinuation treatment was 73 months [12–158]. Twenty-two patients (37%) relapsed with a median time to relapse of 6 months [3–27]. An intermediate or high Sokal score was the only relapse risk factor (HR = 3.32,
p
< 0.05) associated with relapse after TKI discontinuation. TKI discontinuation was possible without relapse for half of the patients in chronic phase CML. In a real-life cohort, a high-risk Sokal score at diagnosis appears to be an adverse prognosis feature for TKI discontinuation.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>35278099</pmid><doi>10.1007/s00277-022-04779-x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2022-05, Vol.101 (5), p.1015-1022 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04086518v1 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Hematology Humans Kinases Laboratories Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - chemically induced Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology Leukemia, Myeloid, Chronic-Phase Life Sciences Medical prognosis Medicine Medicine & Public Health Oncology Original Article Protein Kinase Inhibitors - adverse effects Recurrence Remission (Medicine) Retrospective Studies Stem cells |
| title | Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T04%3A24%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discontinuation%20of%20tyrosine%20kinase%20inhibitor%20in%20chronic%20myeloid%20leukemia:%20a%20retrospective%20cohort%20in%20east%20occitania&rft.jtitle=Annals%20of%20hematology&rft.au=Robin,%20J.%20B.&rft.date=2022-05-01&rft.volume=101&rft.issue=5&rft.spage=1015&rft.epage=1022&rft.pages=1015-1022&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-022-04779-x&rft_dat=%3Cproquest_hal_p%3E2648322798%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2648322798&rft_id=info:pmid/35278099&rfr_iscdi=true |